{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:14:33Z","timestamp":1787015673743,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1009,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Amphotericin-B (AmB) is an essential medication for the treatment of life-threatening systemic mycoses but the incidence and risk factors for acute kidney injury (AKI) after its administration are not known in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Determine the incidence of and risk factors for AKI in dogs receiving AmB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-one client owned dogs receiving AmB for the treatment of systemic mycoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study. Signalment, potential risk factors, AKI development (creatinine \u22650.3\u2009mg\/dL from baseline), drug formulation (deoxycholate [AmB-D] or lipid complex [ABLC]), dose, and treatment duration were recorded. The probability of an AKI diagnosis was evaluated using a log-rank test. The incidence of AKI and odds ratios were calculated for potential risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incidence of AKI was 5\/12 (42%) for dogs receiving AmB-D and 14\/39 (36%) for dogs receiving ABLC. Of the 19 dogs that developed AKI, 16 (84%) continued treatment after a pause in the planned dosing protocol. Fifty percent of dogs received a cumulative dose of 6.9\u2009mg\/kg for AmB-D and 22.5\u2009mg\/kg for ABLC (P\u2009&amp;lt;\u2009.01) at time of AKI diagnosis. ICU hospitalization (odds ratio [OR] 0.21, 95% confidence interval [CI]: 0.58-0.87) and inpatient status (OR 0.25, 95% CI: 0.07-0.86) were associated with decreased odds of AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Incidence of AKI with AmB is common but does not always preclude continued treatment. The incidence of AKI is similar between AmB-D and ABLC, but dogs receiving ABLC tolerated a higher cumulative total dose before AKI diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16728","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:08:21Z","timestamp":1683353301000},"page":"1030-1037","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of acute kidney injury in dogs with systemic mycotic infections treated with amphotericin B (1996-2020)"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-7709","authenticated-orcid":false,"given":"Jennifer C.","family":"Chan","sequence":"first","affiliation":[{"name":"William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California , Davis, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-1442","authenticated-orcid":false,"given":"Jonathan","family":"Dear","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California Department of Medicine & Epidemiology, , Davis, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1445-5113","authenticated-orcid":false,"given":"Carrie","family":"Palm","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California Department of Medicine & Epidemiology, , Davis, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3426-6352","authenticated-orcid":false,"given":"Krystle","family":"Reagan","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California Department of Medicine & Epidemiology, , Davis, California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"3","key":"2026020302563932500_jvim16728-bib-0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0002","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2013.02.038","article-title":"Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations","volume":"447","author":"Serrano","year":"2013","journal-title":"Int J Pharm"},{"key":"2026020302563932500_jvim16728-bib-0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rvsc.2017.12.005","article-title":"Comparison of conventional and lipid emulsion formulations of amphotericin B: pharmacokinetics and toxicokinetics in dogs","volume":"117","author":"Nieto","year":"2017","journal-title":"Res Vet Sci"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0005","first-page":"e16","article-title":"Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs","volume":"41","author":"Bing\u00f6l","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020302563932500_jvim16728-bib-0006","first-page":"449","article-title":"Nephrotoxic tubular damage and calcium deposition following amphotericin B therapy","volume":"43","author":"Wertlake","year":"1963","journal-title":"Am J Pathol"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0007","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1172\/JCI115240","article-title":"Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats","volume":"87","author":"Sawaya","year":"1991","journal-title":"J Clin Invest"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0008","first-page":"23","article-title":"Nephrotoxicity of amphotericin B in dogs: a comparison of two methods of administration","volume":"53","author":"Rubin","year":"1989","journal-title":"Can J Vet Res"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0009","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1198-743X.2004.00963.x","article-title":"Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain","volume":"10","author":"Aguado","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0609.1996.tb01348.x","article-title":"Lipid complex (Abelcet\u00ae) in the treatment of invasive mycoses: the north American experience","volume":"56","author":"Lister","year":"1996","journal-title":"Eur J Haematol Suppl"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/AAC.41.5.886","article-title":"Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats","volume":"41","author":"Bhamra","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0013","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.85.16.6122","article-title":"Unusual lipid structures selectively reduce the toxicity of amphotericin B","volume":"85","author":"Janoff","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0014","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1023\/A:1018997730462","article-title":"Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs","volume":"16","author":"Bekersk","year":"1999","journal-title":"Pharm Res"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0015","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2460\/javma.1996.209.12.2073","article-title":"Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs","volume":"209","author":"Krawiec","year":"1996","journal-title":"J Am Vet Med Assoc"},{"key":"2026020302563932500_jvim16728-bib-0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.rvsc.2020.01.003","article-title":"Correlation between renal histopathology and renal ultrasound in dogs","volume":"129","author":"Burti","year":"2020","journal-title":"Res Vet Sci"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0017","first-page":"1","article-title":"Correlation of renal histopathology with renal echogenicity in dogs and cats: an ex-vivo quantitative study","volume":"11","author":"Zotti","year":"2015","journal-title":"BMC Vet Res"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/vru.12755","article-title":"Renal ultrasonographic abnormalities are associated with low glomerular filtration rate calculated by scintigraphy in dogs","volume":"60","author":"Mattei","year":"2019","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020302563932500_jvim16728-bib-0019","article-title":"IRIS Grading of Acute Kidney Injury","author":"Cowgill","year":"2016"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0020","first-page":"1","article-title":"Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan","volume":"10","author":"Takazono","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0021","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1128\/AAC.00525-15","article-title":"Incidence, predictors, and impact on hospital mortality of amphotericin B nephrotoxicity defined using newer acute kidney injury diagnostic criteria","volume":"59","author":"Rocha","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020302563932500_jvim16728-bib-0022","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8629891","article-title":"Renal recovery following liposomal amphotericin B-induced nephrotoxicity","volume":"2019","author":"Personett","year":"2019","journal-title":"Int J Nephrol"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0023","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/myc.12801","article-title":"Cost-effectiveness of amphotericin B formulations in the treatment of systemic fungal infections","volume":"61","author":"Borba","year":"2018","journal-title":"Mycoses"},{"key":"2026020302563932500_jvim16728-bib-0024","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbareth","year":"2001","journal-title":"Am J Med"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0025","article-title":"Evaluation of total body weight versus adjusted body weight liposomal amphotericin B dosing in obese patients","volume":"65","author":"Ting","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2026020302563932500_jvim16728-bib-0026","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/516321","article-title":"Amphotericin B use in a community hospital, with special emphasis on side effects","volume":"26","author":"Pathak","year":"1998","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.1111\/jvim.16817","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000}}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/3\/1030\/66657652\/jvim16728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/37\/3\/1030\/66657652\/jvim16728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:56:49Z","timestamp":1770105409000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/37\/3\/1030\/8447846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16728","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"2022-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}